- Dr. Liew awarded Malaysia's Darjah Yang Mulia Pangkuan Negeri -
TORONTO, Aug. 20 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing simple blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that its co-founder and Chief Scientific Officer, Dr. CC Liew, was awarded the Darjah Yang Mulia Pangkuan Negeri (DMPN), a State Honour given by the Governor of Penang in Malaysia. Conferred on prominent people who have served the nation or who excel in their professions, this honour carries with it the title of "Datuk", which is similar to a knighthood in Britain. This award is limited to 150 living persons at any given time.
"We are very proud that this honour has been bestowed on Dr. Liew for demonstrating excellence in the field of disease-specific genomics," said K. Wayne Marshall, MD, PhD, President and Chief Executive Officer of GeneNews. "Through Dr. Liew, GeneNews has formed a strong relationship with the Malaysian scientific community. With Malaysia having made a commitment to becoming a major player in the biotechnology sector in South East Asia, Dr. Liew's growing reputation will only further enhance our ability to collaborate with researchers in this region."
In addition to his role as Chief Scientist Officer of GeneNews, Dr. Liew currently holds the positions of Visiting Professor of Medicine and Founding Director of the Cardiovascular Genome Unit at Brigham and Women's Hospital, Harvard Medical School, and Professor Emeritus at the University of Toronto.
GeneNews is focussed on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product in development, ColonSentry(TM), is a blood-based test that can detect colon cancer. For more information on GeneNews, visit http://www.genenews.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
|SOURCE GeneNews Limited|
Copyright©2007 PR Newswire.